Detection of SARS-CoV-2 with RAPID: A prospective cohort study

321 subjects

Highlights
RAPID shows high accuracy, sensitivity, and specificity in prospective cohort study
RAPID was successfully validated using 321 clinical samples
Effective point-of-care diagnosis of a heterogeneous sample set

Torres et al., iScience 25, 104055
April 15, 2022 © 2022 The Authors.
https://doi.org/10.1016/j.isci.2022.104055
Detection of SARS-CoV-2 with RAPID: A prospective cohort study

Marcelo D.T. Torres, Lucas F. de Lima, André L. Ferreira, William R. de Araujo, Paul Callahan, Antonio Dávila, Jr., Benjamin S. Abella, and Cesar de la Fuente-Nunez*

SUMMARY

COVID-19 has killed over 6 million people worldwide. Currently available methods to detect SARS-CoV-2 are limited by their cost and need for multistep sample preparation and trained personnel. Therefore, there is an urgent need to develop fast, inexpensive, and scalable point-of-care diagnostics that can be used for mass testing. Between January and March 2021, we obtained 321 anterior nares swab samples from individuals in Philadelphia (PA, USA). For the Real-time Accurate Portable Impedimetric Detection prototype 1.0 (RAPID) test, anterior nare samples were tested via an electrochemical impedance spectroscopy (EIS) approach. The overall sensitivity, specificity, and accuracy of RAPID in this cohort study were 80.6%, 89.0%, and 88.2%, respectively. We present a rapid, accurate, inexpensive (<$5.00 per unit), and scalable test for diagnosing COVID-19 at the point-of-care. We anticipate that further iterations of this approach will enable widespread deployment, large-scale testing, and population-level surveillance.

INTRODUCTION

COVID-19 has killed millions of people (World Health Organization, 2022) and continues to threaten healthcare systems worldwide. The widespread use of currently available diagnostics has been hampered by their high production cost, lack of scalability, and relatively slow detection times. Therefore, easy-to-use, low-cost, and rapid diagnostic tests are urgently needed.

Electrochemical impedance spectroscopy (EIS) is a technique traditionally used to characterize the surface of electrode materials and well suited to detect binding events between an agent and its recognition element functionalized onto a transducer surface (Bertok et al., 2019; Lisdat and Schafer, 2008). Here, we describe the application of RAPID 1.0 (Real-time Accurate Portable Impedimetric Detection prototype 1.0) for simple, inexpensive, and rapid diagnosis of SARS-CoV-2 clinical samples (Figure 1).

RAPID is an electrochemical biosensor that measures changes in the resistance to charge transfer (Rct) of the redox probe [Fe(CN)6]3-/4-, which is induced when the SARS-CoV-2 spike protein binds to an electrode previously functionalized with human angiotensin-converting enzyme-2 (ACE2) (Torres et al., 2021). By using EIS, the binding between the spike protein and ACE2 can be captured via the generation of an electrochemical signal. Compared to other techniques, RAPID (US$4.67) is around 7–10 times cheaper than RT-PCR and at least two times cheaper than RT-LAMP and other low-cost electrochemical techniques (Alafeef et al., 2020), and it is as inexpensive as high-throughput serological ELISA tests (La Marca et al., 2020). The detection time of the RAPID assay (4 min) is substantially faster than conventional techniques (e.g., RT-PCR – 45 min) and as rapid as the fastest COVID detection methods reported to date (Broughton et al., 2020; Jiao et al., 2020; de Lima et al., 2021; Moitra et al., 2020; Rashed et al., 2021; Torrente-Rodrı́guez et al., 2020). To assess the clinical performance of this diagnostic platform, here, we performed an accuracy study aimed at detecting SARS-CoV-2 in anterior nare samples and compared the results obtained to those from RT-PCR, the gold standard test for COVID-19 diagnosis.

RESULTS

Cohort details

Clinical enrollment was performed over 10 weeks between January and March 2021, following the period with the most COVID-19 cases in Philadelphia (from November to December 2020), where an average of...
40,000 tests were performed with around 500 daily COVID-19 cases confirmed (prevalence of \(-1.25\%\) from November to December) (Figure 2A). All samples collected for the study were aliquoted and frozen at \(-80^\circ\text{C}\) promptly after collection. The anterior nare samples were immersed in VTM following the Food and Drug Administration (FDA) recommendation for regulatory applications (Food and Drug Administration (FDA), 2021). We analyzed a total of 321 nare swab samples from incoming patients that agreed to donate their samples.

**Analysis of the clinical samples**

Clinical samples were incubated for 2 min onto the surface of the electrode, as this was determined to be the optimal amount of time needed to ensure viral detection using RAPID (Torres et al., 2021). The modified electrode favors rapid interaction kinetics between the SARS-CoV-2 spike protein and immobilized ACE2 (kinetics constant rate of \(10^4\,\text{M}^{-1}\text{s}^{-1}\); Yang et al., 2020). RAPID’s results are available within 4 min (2 min of sample incubation +2 min to perform the EIS analysis), which is faster than currently used methods for diagnosing COVID-19 (Bhalla et al., 2020). An additional 4 min were needed to run each blank; however, we did not consider this when calculating our testing time because the blanking step was performed prior to clinical sample analysis. Before starting our clinical study, we calibrated our biosensor using solutions of inactivated SARS-CoV-2 ranging from \(10^1\) to \(10^6\) PFU mL\(^{-1}\). Complete clinical data paired with the
gold-standard method RT-PCR were used to confirm the COVID-19 status of each of the 321 samples (Figure 2B). We obtained a total of 31 positive and 290 negative COVID-19 samples. RAPID demonstrated high sensitivity (80.7%), specificity (89.0%), and accuracy (88.2%) (Tables 1 and S1. Diagnosis of anterior nare samples using RAPID), when using a cut-off value of 0.100 for the normalized RCT. The presence or absence of symptoms and other medical conditions did not interfere with the results obtained with RAPID, and no correlation was found between other medical conditions, race, gender, or age with the false positives and negative data obtained (Data S1. Patient demographic and clinical status). Compared to other electrochemical methods, molecular tests, colorimetric assays, and diagnostic tests reported in the literature (Table 2), RAPID presents one of the highest sensitivities reported to date (LOD of 2.8 fg mL\(^{-1}\) SARS-CoV-2 spike protein). In addition, RAPID displays a rapid detection time for SARS-CoV-2 (4 min) and is low cost (<US$5.00) compared to other diagnostic tests (Alafeef et al., 2020; Broughton et al., 2020; Jiao et al., 2020; Moitra et al., 2020; Qiu et al., 2020; Rashed et al., 2021; Torrente-Rodrı´guez et al., 2020; Yakoh et al., 2021; Zhao et al., 2021).

DISCUSSION

Currently, available diagnostic tests do not provide a sufficiently accurate, rapid, and affordable diagnosis of COVID-19. For instance, commercial SARS-CoV-2 antigen tests only detect virus concentrations characteristic of later stages of the disease at which patients are already highly infectious (Corman et al., 2021), thus not accurately controlling viral spread. RT-PCR, the gold standard for testing, presents optimal accuracy 3–5 days after the onset of symptoms (Boum et al., 2021). The affordability aspect is also particularly important if we are to ensure health equity and increased access to valuable tools, such as diagnostic tests, for preventing viral spread in disadvantaged communities and low-resource settings.

In this prospective cohort study, we assessed the performance of RAPID using 321 anterior nare swab samples from a diversified pool of subjects with ages ranging from 18 to 78 years old, different races, genders, COVID-19-related symptoms, and other medical conditions (Table 3). The clinical prevalence of positive COVID-19 cases in the set of samples analyzed was 9.7%, which is higher than the mean observed for the same period in Philadelphia (1%–2%; Figure 2). We did not find statistical correlations between the erroneously diagnosed samples by RAPID and the clinical status or any relevant information obtained from the participants (Table 3 and Data S1. Patient demographic and clinical status). False-positive results may be due to the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers that may interact with RAPID’s ACE2-modified electrode. However, the lack of information about the

Figure 2. Clinical study in the context of the COVID-19 pandemic in Philadelphia

(A) Number of tests, number of cases, and prevalence of COVID-19 in Philadelphia as per official records (Centers for Disease Control and Prevention, 2021).

(B) Number of tests, number of cases, and prevalence in our retrospective cohort study. Part of this figure was created with BioRender.com.
medication usage of participants limited our ability to draw such a correlation. Biofouling constitutes another important source of potential errors. Biofouling consists of non-specific interactions between the electrodic surface and proteins, lipids, and other biomolecules such as amino acids and glycoproteins that are part of complex clinical samples. These effects have been reported in the literature for complex biological samples (Jamal et al., 2020; Zou et al., 2020) and discussed in our previous work (Torres et al., 2021). Given that the goal of this study was to assess the suitability of the RAPID approach for point-of-care applications while obviating the need for sophisticated infrastructure or multistep analysis, we avoided performing any pretreatment of the samples and, instead, focused our efforts on enhancement of the robustness of the biosensor through the blocking of remaining active sites of the electrode with bovine serum albumin and the addition of a permselective Nafion layer to help prevent biofouling. However, some molecules may still cross the protective layer and adsorb onto the surface of the electrode, thus hindering electron transfer of the redox probe (potassium ferricyanide/ferrocyanide). This will cause higher resistivity, resulting in a similar effect to that observed when the viral spike protein interacts with the ACE2 immobilized on the surface of the electrode. An approach to help decrease the false-positive rate involves increasing the cut-off value of the method, which in turn decreases the specificity issues but also decreases RAPID’s sensitivity. For example, if we change the cut-off value of RAPID to \((Z-Z_0)/Z_0 \geq 0.127\) instead of \((Z-Z_0)/Z_0 \geq 0.100\) to express a positive diagnosis, the specificity of the method is enhanced to 92.07% but its sensitivity is reduced to 74.2%. The false-negative results (6 out of 31 samples) obtained by RAPID can be related to the low viral loads (i.e., lower than RAPID’s limit of detection; 6.29 fg mL\(^{-1}\) spike protein) of some of the clinical samples. Sample collection during the cohort study, involving self-collection, may contribute to the false-negative rate obtained. RAPID is an inexpensive and portable alternative to existing COVID-19 tests, allowing for decentralized diagnosis at the point-of-care. The fast detection (4 min) enabled by our approach is significantly lower than commercially available tests (Kaushik et al., 2020; Rashed et al., 2021; Uhteg et al., 2020), and could potentially be lowered further by using alternative recognition agents, such as engineered versions of human ACE2 with enhanced selective binding toward SARS-CoV-2, or engineered receptors (e.g., antibodies) to the SARS-CoV-2 spike protein (Chan et al., 2020).

Finally, RAPID is amenable to multiplexing to allow detection of emerging biological threats such as bacteria, fungi, and other viruses, simply by adding other recognition agents and modifying the disposition of the electrodes (array configuration). Its ability to detect minimal viral particles within a sample allows diagnosing COVID-19 at the onset of the infection. Collectively, its low-cost, rapid detection time, and high analytical sensitivity make RAPID an exciting alternative tool for high-frequency COVID-19 testing and effective population surveillance (Mina et al., 2020).

**Limitations of the study**

The major limitation of this study is the shelf life of the biosensor due to ACE2 denaturation after several days anchored to the surface of the working electrode. Future work will focus on designing ACE2 derivatives possessing an extended shelf life.

**STAR+METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability

### Table 1. Clinical assessment of RAPID detection of SARS-CoV-2

| RAPID  | RT-qPCR  | Sensitivity | Specificity | Prevalence | Accuracy |
|--------|----------|-------------|-------------|------------|----------|
| Positive | Positive (N = 31) | 25/31 (80.6%) | 31/321 (9.7%) | 283/321 (88.2%) |  |
|       | Negative (N = 290) | 32/290 (10.8%) | 258/290 (87.0%) |  |
|       | Total (N = 321) | 57/321 (17.8%) | 289/321 (90.2%) |  |

Positive and negative values obtained by RT-qPCR and sensitivity, specificity, and accuracy of RAPID 1.0 using nare samples.
Table 2. Side-by-side comparison of the analytical features between RAPID and different sensors developed for SARS-CoV-2 detection

| Sensor                  | LOD                  | Target                           | Technique          | Time (min) | Reference                              |
|-------------------------|----------------------|----------------------------------|--------------------|------------|----------------------------------------|
| RAPID                   | 2.8 fg mL⁻¹          | SARS-CoV-2 spike protein         | EIS                | 4          | (Torres et al., 2021)                  |
| LEAD                    | 2.29 fg mL⁻¹         | SARS-CoV-2 spike protein         | SWV                | 6.5        | (de Lima et al., 2021)                 |
| SARS-CoV-2 RapidFlex    | 500 pg mL⁻¹          | SARS-CoV-2 spike protein         | SWV                | 6          | (Rashed et al., 2021)                 |
|                         | 0.1 mg mL⁻¹          | Viral antigen nucleocapsid protein | DPV and OCP-EIS      | 10         | (Torrente-Rodrı´ guez et al., 2020)           |
|                         | 1 μg mL⁻¹            | IgM and IgG antibodies           | SWV                | 3          | (Yakoh et al., 2021)                  |
| DETECTR                 | 10 RNA copies μL⁻¹   | E gene and N gene                | CRISPR technology  | 40         | (Broughton et al., 2020)               |
| COLOR                   | 154 fg mL⁻¹          | SARS-CoV-2 spike protein         | Colorimetric       | 5          | (Ferreira et al., 2021)                |
| SARS-CoV-2@f-AuNPs      | Ct value: 36.5       | Antibody (S, E, and M)           | Colorimetric       | 3          | (Ventura et al., 2020)                |
| Lateral flow immunoassay (LFIA) | ND               | COVID-19 IgG and IgM antibody   | Colorimetric       | 15         | 5                                      |
| DNAzyme and SARS-CoV-2 RNA | 0.01 ng mL⁻¹    | SARS-CoV-2 RNA                   | Colorimetric       | ±5         | (Anantharaj et al., 2020)             |
| RT-LAMP                 | 0.75 RNA copies μL⁻¹ | SARS-CoV-2 RNA                   | Colorimetric       | 15–40      | (Yu et al., 2020)                     |
| LAMP                    | 50 RNA copies μL⁻¹   | SARS-CoV-2 RNA                   | Fluorescence       | >40        | (Ganguli et al., 2020)                |
| Lateral flow immunoassay (LFIA) | 0.65 ng mL⁻¹ | Biotinylated antibody            | Colorimetric       | ND         | (Grant et al., 2020)                  |
| Lateral flow immunoassay (LFIA) | 1 pg mL⁻¹         | Protein-anti-SARS-CoV-2 IgM/IgG | Colorimetric       | 25         | (Liu et al., 2021)                    |
| Lateral flow immunoassay (LFIA) | (IgG) 0.121 U L⁻¹ and (IgM) 0.366 U L⁻¹ | Antibody IgG and IgM | Fluorescent       | 15         | (Zhang et al., 2020)                  |

Antibody (S, E, and M) spike, envelope, and membrane; gold nanoparticles (AuNP), functionalized AuNanos (f-AuNPs), ribonucleic acid (RNA); transcription loop-mediated isothermal amplification (RT-LAMP); Electrochemical impedance spectroscopy (EIS); Differential pulse voltammetry (DPV); Open-circuit potential-electrochemical impedance spectroscopy (OCP-EIS); Square-wave voltammetry (SWV); Reverse transcription loop-mediated isothermal amplification (RT-LAMP); ND (not described).

- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Anterior nare sample collection and processing
- METHOD DETAILS
  - RAPID biosensor preparation
  - RAPID test for SARS-CoV-2 diagnosis
  - RT-PCR analysis
  - Prospective cohort study design and participants
  - Diagnosis and statistical analysis
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.104055.

ACKNOWLEDGMENTS
C.F.-N. holds a Presidential Professorship at the University of Pennsylvania, is a recipient of the Langer Prize by the AIChE Foundation and acknowledges funding from the Institute for Diabetes, Obesity, and Metabolism, the Penn Mental Health AIDS Research Center of the University of Pennsylvania, the National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM138201, and the Defense Threat Reduction Agency (DTRA; HDTRA11810041 and HDTRA1-21-1-0014). Research reported in this publication was supported by the Nemirovsky Prize and by funds provided by the Dean's...
Table 3. Demographic information of the subjects tested

|                      | Total Cohort (n = 321) | Positive Subjects (n = 31) | Negative Subjects (n = 290) |
|----------------------|------------------------|---------------------------|----------------------------|
| **Median age**       | 37 (13)                | 36 (14)                   | 37 (13)                    |
| **Gender**           |                        |                           |                            |
| Male                 | 91 (28%)               | 9 (29%)                   | 82 (28%)                   |
| Female               | 230 (72%)              | 22 (71%)                  | 208 (72%)                  |
| **Race**             |                        |                           |                            |
| Caucasian            | 133 (41%)              | 13 (42%)                  | 120 (41%)                  |
| African American     | 147 (46%)              | 16 (52%)                  | 131 (45%)                  |
| Hispanic             | 13 (4%)                | 2 (6%)                    | 11 (4%)                    |
| Other                | 29 (9%)                | 0                         | 29 (10%)                   |
| **Medical Problems** |                        |                           |                            |
| Asthma               | 66 (21%)               | 7 (23%)                   | 59 (20%)                   |
| Hypertension         | 61 (19%)               | 8 (26%)                   | 53 (18%)                   |
| History of Smoking   | 41 (13%)               | 3 (10%)                   | 38 (13%)                   |
| Diabetes             | 28 (9%)                | 5 (16%)                   | 23 (8%)                    |
| No Medical History   | 176 (55%)              | 16 (52%)                  | 160 (55%)                  |
| **Symptoms**         |                        |                           |                            |
| Cough                | 93 (29%)               | 14 (45%)                  | 79 (27%)                   |
| Headache             | 68 (21%)               | 11 (35%)                  | 57 (20%)                   |
| Fever/Chills         | 67 (21%)               | 11 (35%)                  | 56 (19%)                   |
| Shortness of Breath  | 33 (10%)               | 3 (10%)                   | 30 (10%)                   |
| No Symptoms          | 127 (40%)              | 6 (19%)                   | 121 (42%)                  |

Innovation Fund from the Perelman School of Medicine at the University of Pennsylvania. B.S.A. acknowledges funds provided by the Dean’s Innovation Fund from the Perelman School of Medicine at the University of Pennsylvania. We thank Jonathan A. Epstein for his support. This work was approved by the University of Pennsylvania Institutional Review Board (IRB 844145). All figures were created with BioRender.com.

**AUTHOR CONTRIBUTIONS**

Conceptualization, M.D.T.T., W.R.A., and C.F.-N.; Methodology, M.D.T.T., L.F.L., A.L.F., W.R.A., P.C., and A.D.; Writing – Reviewing & Editing, M.D.T.T., W.R.A., A.D., B.S.A., and C.F.-N.; Supervision, B.S.A. and C.F.-N.; Data Curation, M.D.T.T., L.F.L., A.L.F., W.R.A., P.C., and A.D.

**DECLARATION OF INTERESTS**

A non-provisional patent application has been filed on related work.

Received: August 4, 2021
Revised: January 20, 2022
Accepted: March 7, 2022
Published: April 15, 2022

**REFERENCES**

Alafeef, M., Dighe, K., Moitra, P., and Pan, D. (2020). Rapid, ultrasensitive, and quantitative detection of SARS-CoV-2 using antisense oligonucleotides directed electrochemical biosensor chip. ACS Nano 14, 17028–17045.

Anantharaj, A., Das, S.J., Sharanabasava, P., Lodha, R., Kabra, S.K., Sharma, T.K., and Medigeshi, G.R. (2020). Visual detection of SARS-CoV-2 RNA by conventional PCR-induced generation of DNAzyme sensor. Front. Mol. Biosci. 7, 1–7.

Bertok, T., Lorencova, L., Chocholova, E., Jane, E., Vikartovska, A., Kasak, P., and Tkac, J. (2019). Electrochemical impedance spectroscopy based biosensors: mechanistic principles, analytical examples and challenges towards commercialization for assays of protein cancer biomarkers. ChemElectroChem 6, 989–1003.

Bhalla, N., Pan, Y., Yang, Z., and Payam, A.F. (2020). Opportunities and challenges for biosensors and nanoscale Analytical tools for pandemics: COVID-19. ACS Nano 14, 7783–7807.
Bourn, Y., Fai, K.N., Nicolay, B., Mboringong, A.B., Bebell, I.M., Nifcon, M., Abah, A., Ezaka, R., Eteki, L., Luquero, F., et al. (2021). Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet Infect. Dis. 21, 1089–1096.

Broughton, J.P., Deng, X., Yu, G., Fasching, C.L., Servellita, V., Singh, J., Miao, X., Strether, J.A., Granados, A., Sotomayor-Gonzalez, A., et al. (2020). CRISPR-Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 38, 870–874.

Centers for Disease Control and Prevention. (2022). COVID Data Tracker. US Department of Health and Human Services, CDC, Atlanta, GA. https://covid.cdc.gov/covid-data-tracker/

datatracker-home.

Chan, K.K., Dorosky, D., Sharma, P., Abbasi, S.A., Dye, J.M., Kranz, D.M., Herbert, A.S., and Procko, E. (2020). Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 369, 1261–1265.

Corman, V.M., Haagge, V.C., Blecker, T., Schmidt, M.L., Mühlemann, B., Zuchowski, M., Jo, W.K., Tscheak, P., Möncke-Buchner, E., Müller, M.A., et al. (2020). Comparison of ten commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. Lancet Microbe 2, e311–e319.

de Lima, L.F., Ferreira, A.L., Torres, M.D.T., de Araújo, W.R., and de la Fuente-Nunez, C. (2021). Minute-scale detection of SARS-CoV-2 using a low-cost biosensor composed of pencil graphite electrodes. Proc. Natl. Acad. Sci. U. S. A 118, e2106724118.

de Lima, L.F., Ferreira, A.L., Torres, M.D.T., de Araujo, W.R., and de la Fuente-Nunez, C. (2021). Minute-scale detection of SARS-CoV-2 using a low-cost biosensor composed of pencil graphite electrodes. Proc. Natl. Acad. Sci. U. S. A 118, e2106724118.

Chan, K.K., Dorosky, D., Sharma, P., Abbasi, S.A., Dye, J.M., Kranz, D.M., Herbert, A.S., and Procko, E. (2020). Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 369, 1261–1265.

Corman, V.M., Haagge, V.C., Blecker, T., Schmidt, M.L., Mühlemann, B., Zuchowski, M., Jo, W.K., Tscheak, P., Möncke-Buchner, E., Müller, M.A., et al. (2020). Comparison of ten commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. Lancet Microbe 2, e311–e319.

Moitra, P., Alafeef, M., Dighe, K., Frieman, M.B., and Pan, D. (2020). Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano 14, 7617–7627.

Mürooj, J., Montes, R., and Pan, D. (2018). Trends in electrochemical impedance spectroscopy involving nanocomposite transducers: characterization, architecture surface and bio-sensing. TrAC Trends Anal. Chem. 97, 201–215.

Qi, G., Zuo, T., Han, J., and Li, H. (2020). Development of a SERS-based lateral flow immunoassay for rapid and ultra-sensitive detection of anti-SARS-CoV-2 IgM/IgG in clinical samples. Sensor. Actuator. B Chem. 329, 129196.

Mina, M.J., Parker, R., and Larremore, D.B. (2020). Rethinking covid-19 test sensitivity — a strategy for containment. N. Engl. J. Med. 383, e120.

Moitra, P., Alafeef, M., Dighe, K., Frieman, M.B., and Pan, D. (2020). Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano 14, 7617–7627.

Muñoz, J., Montes, R., and Baeza, M. (2017). Rethinking covid-19 test sensitivity — a strategy for containment. N. Engl. J. Med. 383, e120.

Qi, G., Zuo, T., Han, J., and Li, H. (2020). Development of a SERS-based lateral flow immunoassay for rapid and ultra-sensitive detection of anti-SARS-CoV-2 IgM/IgG in clinical samples. Sensor. Actuator. B Chem. 329, 129196.

Mina, M.J., Parker, R., and Larremore, D.B. (2020). Rethinking covid-19 test sensitivity — a strategy for containment. N. Engl. J. Med. 383, e120.

Moitra, P., Alafeef, M., Dighe, K., Frieman, M.B., and Pan, D. (2020). Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano 14, 7617–7627.

Murzina, V., Nesterov, A., Boldyr, A., and Mina, M.J. (2020). Detection of SARS-CoV-2 in clinical samples using a lateral flow immunoassay. J. Mol. Histol. 51, 1027–1032.
STAR METHODS

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Chemicals, peptides, and recombinant proteins | Human angiotensin converting enzyme 2 (ACE2) | GenScript | Z03484-1 |
| | Sulfuric acid (H\textsubscript{2}SO\textsubscript{4}) | Sigma | 25810S-1L-PC |
| | Potassium chloride (KCl) | Sigma | P3911-1KG |
| | Potassium ferricyanide K\textsubscript{3}[Fe(CN)\textsubscript{6}] | Sigma | 244023-5G |
| | Potassium ferrocyanide K\textsubscript{4}[Fe(CN)\textsubscript{6}] | Sigma | P3289-5G |
| | Bovine serum albumine (BSA) | Sigma | A2153-10G |
| | Glutaraldehyde (GA) | Fisher | S25341 |
| | Nafion | Sigma | S27084-25ML |
| | Phosphate saline buffer (PBS) | VWR | P32200 |

| Software and Algorithms | Squidstat | Admiral Instruments |
|-------------------------|-----------|---------------------|
| | MultiAutolab M101 | Metrohm |

RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Dr. Cesar de la Fuente-Nunez (cfuente@upenn.edu).

Materials availability
This study did not generate new unique reagents.

Data and code availability
Data: The diagnostics results used for analysis and the detailed demographic table are available at Mendelely data (https://doi.org/10.17632/y7f78c8627.1).

Code: This work did not generate any code.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Anterior nare sample collection and processing
The collection of the anterior nare samples was performed by the subjects tested under supervision by clinical research staff at the Penn Presbyterian Medical Center (PPMC). All the demographic information, as well as the presence or absence of symptoms of the individuals tested, are shown in Table 1. The samples were stabilized and stored in viral transport medium (VTM) following CDC guidelines (CDC SOP#: DSR-052-05). The anterior nare samples were maintained on ice during the collection period, separated into identical aliquots and subsequently stored at −80°C and readily tested. Care was taken to ensure samples were thawed only once before testing.

METHOD DETAILS

RAPID biosensor preparation
The testing platform comprises two components: the electrochemical sensor and a potentiostat. The electrochemical sensors were prepared following established protocols (Torres et al., 2021). Briefly, the
portable devices were printed in a three-electrode configuration cell on phenolic circuit board material (2 × 2 cm). Electrically conductive carbon and Ag/AgCl inks were used for the screen-printing process to fabricate the working/auxiliary electrodes and reference electrodes, respectively. The working electrode’s carbon surface was modified using the drop-casting method. First, 4 μL of 25% glutaraldehyde (GA) solution was added for 1 hour at 37°C to allow the formation of a cross-linked polymer, which enabled subsequent anchoring of ACE2 (4 μL at 0.32 mg mL⁻¹). ACE2 was then incubated at 37°C for 1.5 hours. Next, we added 4 μL of bovine serum albumin (BSA) at 1 mg mL⁻¹ and allowed the working electrode (WE) to dry for 0.5 hours at 37°C to stabilize the enzyme and block potential active sites present within the modified carbon electrode, to avoid nonspecific adsorption of other proteins to the glutaraldehyde layer and ensure stabilization of the ACE2 tertiary structure. Since our goal was to simplify the detection of SARS-CoV-2 in complex biological samples, such as anterior nare swabs, we added a 1 wt. % Nafion solution as an additional protective layer. Nafion, an anionic and selective membrane that allows the permeation of cationic species, is commonly used to enhance the sensitivity and robustness of electrochemical sensors (Mauritz and Moore, 2004). The membrane formed by 1 wt. % Nafion solution enhanced the sensitivity of RAPID 1.0, by enabling chemical preconcentration of cation species and protecting the electrode’s surface against biofouling by macromolecules present in biological samples, such as proteins and lipids (e Silva et al., 2020).

**RAPID test for SARS-CoV-2 diagnosis**

SquidStat Plus (Admiral Instruments, software Squidstat) and MultiAutolab M101 (Metrohm, NOVA 2.1) potentiostats were used to record all data. The electrodes were characterized by Cyclic Voltammetry (CV) and EIS techniques using a mixture of 5 mmol L⁻¹ potassium ferricyanide/ferrocyanide in 0.1 mol L⁻¹ KCl solution before and after electrode modification with glutaraldehyde, ACE2, BSA, and Nafion. CVs and EIS were recorded using a potential ranging from 0.7 to −0.3 V at the scan rate of 50 mV s⁻¹ and a frequency ranging from 10⁵ to 10⁻¹ Hz using a sinusoidal signal with 10 mV of amplitude at room temperature, respectively.

Here, we explored the selective binding between ACE2, which was immobilized on the electrode surface, and SARS-CoV-2 spike protein. The receptor ACE2 is the known entry point for the virus in humans, the SARS-CoV-2 spike protein is its binding element (Yang et al., 2020). The interaction between these two molecules leads to lower interfacial electron transfer rates between the redox probe, ferricyanide/ferrocyanide, and the electrode surfaces. To track this change, we monitored the charge-transfer resistance (Rct), i.e., the diameter of the semi-arc on the Nyquist plot, which correlates with the number of spike protein molecules bound to the electrode’s surface (Muñoz et al., 2017). The EIS measurements were performed using 200 μL of a mixture of 5 mmol L⁻¹ ferricyanide/ferrocyanide prepared in a 0.1 mol L⁻¹ KCl solution added after incubating the clinical sample (10 μL of anterior nare sample) for 2 minutes on the electrode surface. A gentle washing step using PBS was performed to remove the sample and any unbound SARS-CoV-2. For the EIS measurement, a sinusoidal signal was applied at room temperature in the frequency range between 10⁵ and 10⁻¹ Hz using a typical open circuit potential of 0.15 V and an amplitude of 10 mV.

**RT-PCR analysis**

For the RT-PCR assays, RNA was extracted and purified using the QIAamp DSP Viral RNA Mini Kit (Qiagen) from a 140 μL aliquot immediately after the samples were collected and all the positive samples were reanalyzed after the cohort study was over. The first step of this process chemically inactivated the virus from the anterior nare samples under highly denaturing conditions (guanidine thiocyanate) and was performed in a biosafety cabinet under BSL-2 enhanced protocols. The remainder of the process was performed at the lab bench under standard conditions using the vacuum protocol as per manufacturer’s instructions. The elution and input volumes used were 140 μL. Next, RNA present in the samples was analyzed in duplicate using the TaqPath™ 1-Step RT-qPCR reagent (Life Technologies) on the Quantstudio 7 Flex Genetic Analyzer (ABI). The oligonucleotide primers and probes for detection of 2019-nCoV were selected from regions of the virus nucleocapsid (N) gene. The panel was designed for specific detection of the 2019-nCoV viral RNA (two primer/probe sets, N1 and N2). An additional primer/probe set to detect the human RNase P gene (RP) in control samples and clinical specimens was also included in the panel (2019-nCoVEUA-01). RNaseP is a single copy human-specific gene and can indicate the number of human cells collected. Table S2. RT-PCR panel primers and probes, lists the CDC-recommended 2019-nCoV RT-PCR primers and probes used for all the experiments.
Prospective cohort study design and participants
The performance of RAPID was assessed using both SARS-CoV-2-positive and negative samples from an ambulatory COVID-19 testing site for the public, led by staff at the Penn Presbyterian Medical Center (PPMC). All participants underwent anterior nare testing for SARS-CoV-2 using CLIA-approved RT-PCR by PPMC staff for testing, and after this testing underwent study procedures. Adult (age > 17 years) subjects were eligible if they (1) underwent PPMC staff-led testing immediately prior to study enrollment, (2) were deemed competent for written consent, (3) were English fluent, and (4) did not have any contraindications to anterior nare samples collection procedures, such as recent facial surgery or active head and neck cancer. Subjects completed standard written consent, and then completed a short survey including demographic information and recent infectious symptoms, if any. Subjects then underwent anterior nasal swabbing supervised by trained clinical research coordinators. This work was approved by the University of Pennsylvania Institutional Review Board (IRB 844145).

Diagnosis and statistical analysis
The $R_{CT}$ values of Nyquist plots obtained using Squidstat Plus (Admiral Instruments) and Multi Autolab M101 (Metrohm) were extracted by the application of an equivalent circuit using the softwares Zahner Analysis and Nova 2.1, respectively. We created an equivalent circuit comprising two semi-arc regions obtained during the electrochemical experiments in the Nyquist plots. The first region is a non-defined semi-arc at a high-frequency range, which is caused by inhomogeneity or defects in the electrode modification step (during drop-casting functionalization) and considerably small ($R_{CT} \sim 10$ $\Omega$) (Bertok et al., 2019; Uygun and Ertugrul Uygun, 2014). The second parallel component of the equivalent circuit comprises an $R_{CT}$, whose signal intensity was proportional to the logarithm of the concentration of SARS-CoV-2, and presented a Warburg element to describe the mass transport (diffusional control).

To diagnose a given sample, we used the normalized $R_{CT}$, defined by the following equation:

$$\text{normalized } R_{CT} = \frac{Z - Z_0}{Z_0}$$

where $Z$ is the $R_{CT}$ of the sample and $Z_0$ is the $R_{CT}$ of the blank solution (VTM).

We set as a cut-off value a 10% change in the $R_{CT}$ when compared to the blank solution, i.e., $(Z-Z_0)/Z_0 \geq 0.100$ to diagnose as a positive result. Such a cut-off threshold considers the limit of quantification (LOQ) value previously obtained for inactivated virus 3.87 PFU mL$^{-1}$ (Torres et al., 2021), thus allowing discrimination between SARS-CoV-2 negative and SARS-CoV-2 positive samples.

**QUANTIFICATION AND STATISTICAL ANALYSIS**
Normalized $R_{CT}$ values extracted from EIS measurements are presented as an average of 3 different replicates for each sample. Graphs were created and statistical tests conducted in GraphPad Prism 9.2.